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EditorialThe Pharmacology of Gene and Cell Therapy
The marketing authorization of Glybera and Strimvelis by the Euro-
pean Medicines Agency (EMA) marked the end of the long and often
troubled road of gene therapy from biological concept to medical
practice. Glybera is a recombinant adeno-associated virus (AAV) vec-
tor designed for gene therapy of lipoprotein lipase deficiency,1 while
Strimvelis is a genetically modified hematopoietic stem cell prepara-
tion for the treatment of severe combined immunodeficiency.2 The
US Food and Drug Administration (FDA) recently filled the gap
for the US market by approving in rapid succession Ymlygic, a genet-
ically modified oncolytic herpes virus, Kymriah and Yeskarta, two
forms of genetically manipulated autologous T cells for immuno-
therapy of cancer, and Luxturna, a recombinant AAV vector for
gene therapy of a rare form of retinal dystrophy. Manymore products
are about to follow because pivotal clinical trials are showing efficacy
and safety in addressing rare genetic disorders as well as refractory
neoplastic diseases. Nevertheless, gene therapy technology is still in
its infancy: manufacturing processes are far from being industrialized
and quality and potency attributes are continuously improving
thanks to innovation and a rapidly evolving analytical toolbox. The
pharmacology of gene therapy is a new science, applying concepts
developed for chemical drugs to extremely complex biological prod-
ucts for which terms such as active principle, dose, purity, strength,
toxicity, biodistribution, shedding, environmental risk, pharmacoki-
netics, and pharmacodynamics must be redefined in a creative,
though equally rigorous, fashion. As an example, the very definition
of “drug” is ill-adapted to heterogeneous preparations of genetically
modified autologous cells, which are individualized therapies by defi-
nition. Regulatory agencies around the world are trying to cope by
providing guidelines and regulations intended to enable development
and marketing of gene therapy in a safe, sensible fashion to avoid un-
necessary delays in making innovative products available to patients.3
This issue of Molecular Therapy – Methods & Clinical Development
provides an update on some outstanding issues in the pharmacology
of gene therapy products. Six articles authored by experts in the field
address manufacturing of vectors and genetically modified cells, vec-
tor-host interactions, and the use of animal models to analyze activity,
potency, biodistribution, pharmacokinetics, toxicity, and immunoge-
nicity of gene therapy products. Rather than providing exhaustive re-
views, the articles assess the state-of-the-art and identify controversy
and future needs in this continuously evolving field, with reference to
the most relevant regulations and guidelines in Europe and the US.
This special issue is meant to raise awareness on the complexity
associated with defining and characterizing the biological and phar-
macological properties of gene and cell therapy products. AAV vec-
tors, lentiviral vectors, and chimeric antigen receptor (CAR)-T cells
serve as examples of different classes of therapeutics that already
proved their market fitness.
AAV vectors are a relatively simple and flexible tool to deliver genes
or gene-modifying nucleic acids to an array of target tissues for aMolecular Therapy: Methods &
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academia and industry. Pennaud-Budloo et al.4 provide an overview
of the current technology used to produce clinical-grade AAV vectors
batches in compliance with the good manufacturing practices
(GMPs) required by both the FDA and EMA. They describe the
two most commonly used production systems (transient transfection
in human HEK293 cells and infection of insect cells by baculovirus
expression vectors), the challenges associated with large-scale pro-
duction, and the potential advantages offered by mammalian stable
cell lines. Much emphasis is given to product characterization, the
type of impurities associated with the different production and puri-
fication systems, and the analytical tools required to detect them in a
quantitative fashion. The quality of the AAV particles and the amount
of defective or “empty” capsids varies with the different production
systems and is discussed in terms of both safety and potency of the
vector preparations. Empty capsids and their impact on the immune
response to AAV vectors are discussed by Colella et al.5 in the context
of the overall immunological consequences of AAV vector adminis-
tration to humans. The authors focus on liver-directed gene therapy
as a paradigm of a therapeutic platform that associates proven clinical
efficacy to specific vector-host interactions and the double-edged
sword of immunization/tolerization. Particular emphasis is given to
the design of transgene expression cassettes and new AAV capsids
and to the pre-clinical studies required to assess efficacy, potency,
toxicity, and humoral and cytotoxic immune responses against vector
and transgene products. The impact of pre-existing anti-capsid im-
munity on the safety and efficacy of AAV-mediated gene therapy
and the correlation between organ growth and long-term vector
persistence are discussed in the context of the existing clinical data
and future clinical trial design. The challenges of building a pre-clin-
ical package for gene therapy medicinal products and the use of ani-
mal models for biodistribution and toxicity studies are discussed by
Silva Lima and Videira,6 focusing, in particular, on EMA require-
ments for clinical trial authorization in Europe. The relevance of
the animal model and the factors determining its suitability for any
intended pre-clinical assessment are given particular emphasis and
described in the context of pharmacology, pharmacokinetics, and
toxicology studies. The use of a risk-based approach is described by
taking two specific cases as examples (Glybera and Imlygic), and
analyzing how choices made in pre-clinical studies impacted the
registration process for both products.
Genetically modified cells are a different class of products with respect
to injectable viral vectors because they are made of a patient-derived
component, most commonly hematopoietic stem cells or T cells, and
a viral vector that mediates integration of a gene expression cassette in
the cell’s DNA. Integration, most frequently obtained by an HIV-
derived lentiviral vector, is a potentially genotoxic event by definition,
as it interrupts the continuity of the genome and may potentially
disrupt (or interfere with the regulation of) endogenous genes. Inser-
tional oncogenesis has been seen in the past as a severe side effect ofClinical Development Vol. 8 March 2018 ª 2018 The Author(s). 181
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mains a safety concern for any integrating vector. Poletti andMavilio7
describe themolecular basis of target site selection by retroviruses and
retroviral vectors, a knowledge derived from over 15 years of research
on the biology of HIV and the severe adverse events observed in gene
therapy clinical trials. The development of high-throughput DNA
sequencing and genome-wide analysis of chromatin structure and
configuration enables detailed understanding of the complexity of
retrovirus-genome interactions, including how integration prefer-
ences of each virus impact the potential genotoxicity of the vectors
derived from them. Biasco et al.8 describe the tools and analytics
available to analyze the integration characteristics and the potential
genotoxicity of vectors developed for clinical applications in both
cell culture and in vivo in the context of pre-clinical studies. They
also describe how to monitor genetically modified cells and their
clonal dynamics in treated patients. These analyses are still relatively
complex and depend on bioinformatic tools that are neither standard-
ized nor validated. Nevertheless, they provide an important biosafety
readout and, in the case of genetic modification of long-lived stem
cells, crucial information on their fate and, ultimately, on the efficacy
of the therapy. In the case of CAR-T cells, which are revolutionizing
cancer therapy despite their relatively short clinical history, integra-
tion-driven genotoxicity is much less of a concern. CAR-T cells are
relatively short-lived and there is little evidence that a mature T cell
or even a T cell progenitor can be “transformed” by a vector-driven
event. On the other hand, their efficacy depends on their pharmaco-
logical properties, which are very different from those of viral vectors
or more conventional biologics. Milone and Bhoj9 review the different
types of CAR-T cells currently under clinical investigation, their cell
kinetics after infusion, and the relationship between kinetic properties
and anti-cancer activity. They also discuss the toxicity associated with
T cell therapies and the relationship between toxicity and therapeutic
efficacy, an intriguing though poorly understood aspect of this form
of gene therapy.
The age of molecular therapies and medicines has arrived. Recent
initial approvals highlight a future wherein we will be able to treat
and cure disease with molecular technologies. We can now look
back at Carl Sagan’s “pale blue dot” that gene therapy once was and
look forward to the expanding possibilities ahead. To accomplish these
goals, we will need to develop a cohesiveness in subspecialties of the182 Molecular Therapy: Methods & Clinical Development Vol. 8 Marchfield (CAR-T cells, DNA, or RNA viruses, etc.), including themethods
used for determining attributes, such as active principle, dose, purity,
strength, toxicity, biodistribution, shedding, environmental risk,
pharmacokinetics and pharmacodynamics, both in animal and hu-
man studies. Standardizing these methods will provide for more
data that can be directly compared throughout the field and used to
predict outcomes, thereby reducing preclinical studies and the risk-
benefit ratio, while increasing the efficacy of early clinical studies.
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